Please note that this product (marketed as Lenvima) was withdrawn from the Community Register of designated orphan medicinal products in July 2018 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 19 March 2015, orphan designation (EU/3/15/1460) was granted by the European Commission to Eisai Europe Limited, United Kingdom, for lenvatinib for the treatment of hepatocellular carcinoma.
The sponsorship was transferred to Eisai GmbH, Germany, in June 2018.
Treatment of hepatocellular carcinoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: